Dr. Rimel on the Importance of BRCA and HRD Testing in Ovarian Cancer
December 19th 2022Bobbie J. Rimel, MD, discusses the importance of testing patients with ovarian cancer for homologous recombination deficiency (HRD) or homologous recombination proficiency (HRP), and BRCA mutation status.
Read More
Dr. Bobbie J. Rimel on Genetic Testing in Ovarian Cancer
March 21st 2016Bobbie J. Rimel, MD, assistant professor, Obstetrics and Gynecology, discusses discovering BRCA mutations early in ovarian cancer patients. Rimel says with the genetic information of knowing which patients harbor which genetic mutations, oncologists can offer their patients treatments such as PARP inhibitors, which are gene-specific.
Read More